Search Results
Your search for ,are matches 21901 pages
Showing 15251 - 15300Closing the Clinical Trial Gap for Adolescents and Young Adults With Cancer
Although overall survival rates for patients with cancer continue to soar—with 14.5 million cancer survivors today1—most of that gain is among pediatric and older adult patients. For adolescents and young adults with cancer—defined by the National Cancer Institute (NCI) as those in the 15- to...
Geriatric Assessment of Transplant-Ineligible Older Adults With Multiple Myeloma: A Novel Approach in the Era of Novel Agents
Myeloma is a disease of aging, with a median age at diagnosis in the United States of 69 years.1 As the population ages, forecasts estimate that, within 20 years, 3 of every 4 people diagnosed with multiple myeloma in the United States will be between the ages of 64 and 84 years.2 In anticipation...
2016 ASH-AMFDP Scholars to Study Malaria, Immunotherapy for Hematologic Malignancies
The American Society of Hematology (ASH) is pleased to announce that Natasha Archer, MD, MPH, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Rayne Rouce, MD, of Baylor College of Medicine, have been selected to participate in the American Society of Hematology-Harold Amos...
Is This the Dawn of Cancer Biosimilars?
The Patient Protection and Affordable Care Act, signed into law in 2010, did more than make it possible for millions of Americans to afford health care; it also established an abbreviated approval pathway for biologic products that are “biosimilar” to, or shown to be “interchangeable” with, a U.S....
Obinutuzumab in Relapsed or Refractory Follicular Lymphoma
On February 26, 2016, obinutuzumab (Gazyva) was approved for use in combination with bendamustine (Bendeka, Treanda) followed by obinutuzumab monotherapy for treatment of patients with follicular lymphoma who have relapsed after or are refractory to a rituximab (Rituxan)-containing regimen.1,2...
Scandinavian Sarcoma Group Trial Shows Continued Benefit With 3 Years vs 1 Year of Adjuvant Imatinib in High-Risk GIST
As reported in the Journal of Clinical Oncology by Heikki Joensuu, MD, PhD, of the Comprehensive Cancer Center Helsinki, Finland, and colleagues, the second planned analysis in the Scandinavian Sarcoma Group XVIII/AIO trial showed a recurrence-free survival benefit and a continued overall survival ...
No Apparent Benefit of Long-Term Mifepristone in the Treatment of Unresectable Meningioma
In a phase III trial (SWOG S9005) reported in the Journal of Clinical Oncology,1 YongLi Ji, MD, PhD, and Claire Verschraegen, MD, of the University of Vermont Cancer Center; and colleagues found no benefit of treatment with the antiprogestin agent mifepristone vs placebo in patients with...
Conquering Cancer With Dr. Kim
There are many different ways to treat cancer: surgery, radiation therapy, chemotherapy, and more, sometimes used alone and sometimes in combination. But, in certain circumstances, the best treatment option for a patient may not look much like treatment at all. Instead of attempting to eliminate...
ASCO University® Launches New Certificate Programs for Advanced Practitioners
The role of advanced practitioners in oncology is growing as the demand for team-based care increases—and with that growth comes a need for training materials specifically tailored to this group. ASCO University®, ASCO’s home for lifelong learning, has collaborated with the Association of Physician ...
Join the Conversation Online at jgo.org
Journal of Global Oncology now offers readers the option to comment on any JGO article. Users can sign in through social media or a Disqus account and share their thoughts with the JGO community. All comments will be moderated by the journal to ensure they are constructive and relevant. Start a...
2016 Pre–Annual Meeting Educational Programs Feature Important Topics for Modern Cancer Care Providers
For oncology professionals looking to maximize their learning and networking opportunities, ASCO will be offering two types of Pre–Annual Meeting Educational Programs ahead of its 2016 Annual Meeting in Chicago this summer. Offered since 2012, Pre–Annual Meeting Seminars are a series of in-depth...
Palbociclib Combined With Fulvestrant in Advanced Breast Cancer Progressing After Endocrine Therapy
On February 19, 2016, palbociclib (Ibrance) was approved for use in combination with fulvestrant (Faslodex) for treatment of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.1,2 In February 2015, palbociclib in...
Cancer Survivorship Research: Learning From the Past to Improve Future Outcomes
Soon after effective therapies for some childhood malignancies were first identified, early leaders in our field had concerns about what would happen to surviving patients as they aged. In 1975, Giulio D’Angio, MD, one of the founders of modern pediatric radiation oncology, presciently called for...
Two Fellows Selected for ASCO’s Inaugural Health Policy Fellowship Program
ASCO has announced the two physicians selected for its new Health Policy Fellowship, which kicked off this past October. Robert M. Daly, MD, and Steve Y. Lee, MD, will be the fellows for the inaugural class, which runs from July 1, 2016, to July 1, 2017. The program, aimed at oncologists in the...
Douglas A. Levine, MD, FACOG, FACS, Appointed Director of Gynecologic Oncology at NYU Langone
Douglas A. Levine, MD, FACOG, FACS, will join the faculty of NYU Langone Medical Center as Director of the Division of Gynecologic Oncology at its Laura and Isaac Perlmutter Cancer Center and the Department of Obstetrics and Gynecology, effective May 15, 2016. Dr. Levine brings an exceptional...
Everolimus in Advanced Neuroendocrine Tumors
On February 26, 2016, everolimus (Afinitor) was approved for treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin that are unresectable, locally advanced, or metastatic.1,2 The drug was previously approved for...
Expert Point of View: David Raben, MD
“Proton therapy may very well offer reduced late toxicities. Reflecting back on past reirradiation studies both within and outside of the cooperative groups, it seems that the late toxicities in this retrospective study were somewhat similar,” said David Raben, MD, Professor of Radiation Oncology...
Markedly Improved Toxicity Rates With Proton-Beam Reirradiation for Recurrent Head and Neck Cancer
Proton-beam radiation therapy may be an attractive option for reirradiation of recurrent head and neck cancer, with encouraging disease control and survival rates and improved toxicity rates compared to photon reirradiation, according to John Han-Chih Chang, MD. Most head and neck cancers present...
Expert Point of View: David Raben, MD
“As radiation oncologists, we have pushed some important envelopes to try to mitigate long-term toxicity,” said David Raben, MD, Professor of Radiation Oncology at the University of Colorado Cancer Center, Aurora, Colorado. “We’ve been able to utilize intensity-modulated radiation techniques to...
Late Toxicity Improved With Response-Adapted Volume De-escalation in Locally Advanced Head and Neck Cancer
Efforts to reduce the late toxicity associated with chemoradiotherapy for locally advanced head and neck squamous cell cancer have focused on radiation therapy dose de-escalation in select populations, according to James Melotek, MD, a radiation oncologist at the University of Chicago. “Patients...
Study Supports an Immune Effect of Chemoradiation in Head and Neck Cancer
Definitive radiation, with or without chemotherapy, induces a combination of immune-stimulating and inhibitory effects in patients with squamous cell carcinoma of the head and neck, according to research presented by Jonathan Schoenfeld, MD, MPhil, MPH, at the 2016 Multidisciplinary Head and Neck...
Mutational Profile May Impact Treatment Decisions for Smokers With Human Papillomavirus–Positive Oropharyngeal Cancer
Smokers whose oropharyngeal tumors are positive for the human papillomavirus (HPV) might need more aggressive treatment for their disease, according to research presented by Jose Zevallos, MD, at the 2016 Multidisciplinary Head and Neck Cancer Symposium in Scottsdale, Arizona.1 Over time,...
Annual Report Cites Continued Decline in Most Cancer Mortality but Trends Toward Increased Liver Cancer Incidence, Mortality
Earlier this month, experts from four major institutions issued the annual Report to the Nation on the Status of Cancer (1975–2012). This year’s report showed that death rates continued to decline for all cancers combined, as well as for most cancer sites for men and women of all major racial and...
FDA Approves Obinutuzumab in Follicular Lymphoma
The U.S. Food and Drug Administration (FDA) has approved obinutuzumab (Gazyva), an anti-CD-20 monoclonal antibody, for use in combination with bendamustine (Bendeka, Treanda) followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma who relapsed after, or are...
FDA Approves Crizotinib for ROS1-Positive Metastatic Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration has approved the tyrosine kinase inhibitor crizotinib (Xalkori) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are ROS1-positive. Crizotinib was first approved in 2011 for the treatment of patients whose tumors are ...
SSO 2016: Largest Surgical Oncology Conference Yet
The Society of Surgical Oncology (SSO) Annual Cancer Symposium is not only the largest surgical oncology conference in the world, but the 69th meeting, recently held in Boston, is the group’s largest ever, according to SSO Past President Jeffrey A. Drebin, MD, PhD, the John Rhea Barton Professor...
Surgeons—Yes, Surgeons—Have a Role in Translational Cancer Research
Surgeons are clearly more comfortable in the operating room than the laboratory, but there is a place for them in translational cancer research as well, according to one surgeon who has led cutting-edge research in pancreatic cancer. “Translational studies require access to patients, to tissue, and ...
Phone Triage System Offers Potential to Reduce Patient Visits to the Emergency Department for Cancer Treatment–Related Symptoms
A quality improvement initiative to reduce the reliance of patients on visits to the emergency department for treatment of side effects related to cancer treatment was reported to be highly effective, according to early findings from a new study. 1 The strategy, involving a telephone triage...
Update on CancerLinQ: A Rapid Health-Care Learning System
On March 26, 2013, ASCO announced that it had completed a prototype of CancerLinQ™, the Society’s groundbreaking health information–technology initiative to achieve higher quality, higher value cancer care with better outcomes for patients. At this year’s 2016 ASCO Quality Care Symposium, Robert S. ...
Regulators Embrace Immunotherapy
The Cancer Drug Development Forum exists to provide, as the name implies, a meeting place to bring together academia, the pharmaceutical industry, and most important regulators for full and frank discussions to facilitate anticancer drug development. In the recent past, the Cancer Drug Development...
Anticoagulation in Patients With Cancer: Understanding the Complexities of Prophylaxis and Management
Venous thromboembolic events are more prevalent in patients with cancer than in persons without it. Cancer is associated with a high rate of venous thromboembolism recurrence, bleeding, requirement for long-term anticoagulation, and reduced quality of life. Moreover, thrombosis is the second most...
Chronic Lymphocytic Leukemia: The Golden Drug Only for Golden Agers?
As reviewed in this issue of The ASCO Post, Burger and colleagues recently reported findings of the RESONATE-2 trial of ibrutinib (Imbruvica) vs chlorambucil (Leukeran) as initial therapy for elderly patients with chronic lymphocytic leukemia (CLL).1 The study met its primary endpoint of...
Neurofeedback Reduces Pain, Increases Quality of Life for Cancer Patients Suffering From Chemotherapy-Induced Neuropathy
A new study from The University of Texas MD Anderson Cancer Center evaluating the use of neurofeedback found a decrease in the experience of chronic pain and an increase in quality of life among patients with neuropathic pain. The study was presented at the annual meeting of the American...
Families of Cancer Decedents See Early Hospice, ICU Avoidance, and Death Outside the Hospital as Better End-of-Life Care
Families of patients dying with lung or colorectal cancer judged end-of-life care as better when it was less aggressive, involved earlier hospice, avoided intensive care unit (ICU) admission, and included death outside of the hospital, according to a study reported by Wright et al in JAMA. Study...
Specific Form of CYP3A7 Gene Associated With Poor Outcomes for Patients With Several Cancer Types
Among patients with breast cancer, lung cancer, or chronic lymphocytic leukemia (CLL), those who had a specific form of the CYP3A7 gene (CYP3A7*1C) had worse outcomes compared with those who did not have CYP3A7*1C. This may be related to how the patients metabolize the therapeutics used to treat...
Processed Meat Consumption May Increase Risk of Breast Cancer for Latinas
Latinas who eat processed meats such as bacon and sausage may have an increased risk for breast cancer, according to a new study that did not find the same association among white women. The study, published by Kim et al in Cancer Causes & Control, suggests that race, ethnicity, genetics,...
Dietary Glycemic Index Linked to Lung Cancer Risk in Non-Hispanic White Populations
Consuming a diet with a high glycemic index was independently associated with an increased risk of developing lung cancer in non-Hispanic whites, according to a new epidemiologic study from The University of Texas MD Anderson Cancer Center. This research, published by Melkonian et al in Cancer...
Laboratory Study Explores How High-Fat Diet Influences the Development of Intestinal Tumors
A study published by Beyaz et al in Nature reveals how a high-fat diet makes the cells of the intestinal lining more likely to become cancerous. It joins a growing body of research that finds obesity and eating a high-fat, high-calorie diet are significant risk factors for many types of cancer....
Site of Death, Health-Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in Developed Countries
In a study reported in JAMA, Bekelman et al assessed the site of death, health-care utilization, and hospital expenditures among patients aged ≥ 65 years dying with cancer in Belgium, Canada, England, Germany, the Netherlands, Norway, and the United States. The United States had lower...
Finnish Study Identifies Increased Cancer Risks in Patients With Neurofibromatosis Type 1
In a Finnish study reported in the Journal of Clinical Oncology, Uusitalo et al found that patients with neurofibromatosis type 1 (NF1) were at increased risk of other cancers in addition to nervous system disease. The study included data from a population-based series of patients with...
Fosaprepitant Combination Reduces Risk of Emesis During Chemoradiotherapy for Cervical Cancer
The addition of fosaprepitant (Emend) to palonosetron and dexamethasone reduced the risk of emesis during 5 weeks of chemoradiotherapy for cervical cancer, according to the phase III GAND-emesis trial reported in The Lancet Oncology by Ruhlmann et al. Study Details In the double-blind trial, 234...
ASCO Report Finds U.S. Cancer Care System Ill-Equipped to Deliver New Advances to Patients
As the nation embarks on an ambitious “moonshot” to accelerate progress against cancer, our system for delivering today's cancer treatments must be better prepared to bring advances to all patients, warns a new report from ASCO. The State of Cancer Care in America: 2016, published...
Early MRI Screening Reduces Risk of Breast Cancer Death for Survivors of Childhood Hodgkin Lymphoma
Researchers at Princess Margaret Cancer Centre have confirmed in a screening effectiveness study that early screening with magnetic resonance imaging (MRI) can reduce breast cancer mortality for female survivors of childhood Hodgkin lymphoma who received chest radiation. The findings published by...
Single Dose of Trastuzumab Kickstarts Immune Response in Certain Breast Cancers
A tumor’s immune response to a single dose of the HER2 inhibitor trastuzumab (Herceptin) predicted which patients with HER2-positive breast cancer would respond to the drug on a more long-term basis, according to the results of a study published by Varadan et al in Clinical Cancer Research....
Frequent Copy Number Gain of Genes for PD-1 Ligands in Squamous Cell Carcinoma of the Cervix or Vulva
In a study reported in JAMA Oncology, Howitt et al identified copy number gain of genes encoding programmed cell death protein 1 (PD-1) ligands in a sizable proportion of patients with squamous cell carcinoma of the cervix or vulva. Study Details The study involved fluorescence in situ...
Severe Adverse Event Clusters Identified Using NCI Common Terminology Criteria in Advanced Prostate Cancer
Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), researchers from Columbia University, New York, and Fred Hutchinson Cancer Research Center, Seattle, identified six severe adverse events clusters in patients with advanced prostate cancer. The...
FDA Approves Crizotinib for ROS1-Positive Metastatic NSCLC
The U.S. Food and Drug Administration today approved the tyrosine kinase inhibitor crizotinib (Xalkori) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are ROS1-positive. Crizotinib was first approved in 2011 for the treatment of patients...
Combination Therapy May Be Better Than Radiotherapy Alone to Treat Aggressive Brain Cancer, According to Early Study
Radiotherapy effectively damages brain tumors, but the cancer cells can repair themselves in order to live on. Now, researchers at Sidney Kimmel Cancer Center at Thomas Jefferson University have tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumor to mend...
Researchers Find Possible Association Between Oral Bacteria and Esophageal Cancer
University of Louisville School of Dentistry researchers have found that a bacterial species responsible for gum disease, Porphyromonas gingivalis, is present in 61% of patients with esophageal squamous cell carcinoma. The findings, published by Gao et al in Infectious Agents and Cancer, only...
Family Perspectives Support Advance Care Planning With Patient Preferences in End-of-Life Care
Three measures of aggressive end-of-life care “were associated with relatively large differences in family member–reported quality ratings for end-of-life care and a lower likelihood that patients with advanced-stage cancer received care congruent with their preferences,”...
